TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET

What it is

TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET is how the CMS NADAC file names this product. The FDA NDC Directory lists it as “tenofovir disoproxil fumarate tablets” and “tenofovir disoproxil fumarate”, as its NDCs’ listings variously write the nonproprietary name.

FDA gives its dosage form as “tablet, film coated”, “tablet” and “tablet, coated” and its route as oral.

FDA lists 11 labelers (the companies named on the label) for its NDCs, among them Major Pharmaceuticals, NorthStar RxLLC and Camber Pharmaceuticals, Inc.

FDA lists it under 2 Established Pharmacologic Classes: Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor and Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor.

The NADAC file of 2026-10-14 prices it under 12 NDCs (National Drug Codes); the FDA directory lists 11 of them.

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $8.81 for 30 tablets (30 × $0.29381 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

What NADAC measures · Why 30 tablets · NADAC explanation codes

The 11 labelers

Other strengths, forms and brands

1 other product in the NADAC file shares an FDA nonproprietary name with TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET.

Part D is one average per brand and generic name, over every strength and form.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18

Compared with its class

The middle of its 12 NDCs’ NADAC prices is $0.29381 per EA filed.

Of the 28 other products in FDA’s Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 27 have a higher middle NADAC price and 1 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Of the 28 other products in FDA’s Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class priced per EA, 28 have a higher middle NADAC price and 0 a lower one. The one in the middle is VEMLIDY 25 MG TABLET, at $51.98384 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

How the class comparison works

What Medicare paid

We don’t know yet; the card above says why.

Which Medicare figure OpenBill compares · How Part D is matched · How Part B is matched

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

• What is your cash price for 30 tablets? Is it lower than what I would pay through my insurance?
• These are questions about price, not medical advice. Do not change or stop a medicine without talking to your prescriber or pharmacist.